Targeting CBFA2T3 in leukemia, especially acute lymphoblastic leukemia that expresses the E2A-Pbx1 fusion protein, is also supported by an increasing body of evidence [58,62,63]. This evidence concerns the gene PBX1 and acute lymphoblastic leukemia.